Se desexas distinguir vos teus produtos, servizos ou ambos os dous doutra empresa, é posible que necesites unha marca ou nome comercial. Descobre que son, en que consiste ou seu procedemento de rexistro e que implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Se tes un novo dispositivo, produto ou procedemento que resolva un problema técnico ou teña unha vantaxe práctica, existen distintas formas de protexelo en España e noutros países. Descobre como facelo.
A túa innovación reside na estética, a ornamentación ou a aparencia do teu produto? Protéxea mediante un deseño industrial. Descobre que dereitos confire ou rexistro e como realizar a tramitación.
As indicacións xeográficas protexen o nome dun produto orixinario dunha zona xeográfica, á cal lle debe unha determinada calidade, reputación ou outra característica. Descobre que son, en que consiste o seu procedemento de rexistro e que beneficios conceden.
As patentes publicadas en todo ou mundo son unha valiosa fonte de información científica, técnica e comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Ése emprendedor/a ou unha empresa e queres potenciar e mellorar a rendibilidade do teu negocio protexendo de forma adecuada vos activos intangibles dá túa organización, neste espazo atoparás ou necesario.
122
resultados
Última actualización
07/12/2025 [07:04:00]
Resumen de: US2025368767A1
Methacrylate-based functionalized dendronized polyglycerol polymers are provided. These polymers are highly biocompatible and less anticoagulant, form thread-like single chain fibers and show excellent inhibition against respiratory viruses such as SARS-CoV-2 and HSV-1. They can be easily used for forming degradable hydrogels together with a crosslinker.
Resumen de: WO2025246679A1
Provided are a broad-spectrum coronavirus-neutralizing antibody and a use thereof. The antibody CYFN1006-1 comprises a heavy chain variable region VH and a light chain variable region VL, wherein the VH comprises CDRH1 to CDRH3 having amino acid sequences as shown in SEQ ID NOs: 1-3; and the VL comprises CDRL1 to CDRL3 having amino acid sequences as shown in SEQ ID NOs: 4-6. CYFN1006-1 is a broad-spectrum highly-efficient coronavirus-neutralizing antibody, can efficiently neutralize all currently circulating SARS-CoV-2 variants, shows medium efficacy on SARS-CoV, and provides a new choice for solving the problems of viral escape and drug resistance encountered in the application of monoclonal antibody passive immunotherapy against novel coronavirus infection.
Resumen de: WO2025250893A1
Provided herein are methods of analyzing antibody binding. In some embodiments, the methods comprise contacting a set of SARS-CoV-2 protein variant functionalized nanoparticles (MNPs) with a set of antibodies, and contacting a set of ACE2 protein functionalized nanoparticles (MNPs) with the set of antibodies and a set of competition probes that comprise the SARS-CoV-2 protein variant. In some embodiments, the methods also include detecting binding, if any, of the SARS-CoV-2 protein variant functionalized MNPs with the set of antibodies and binding, if any, of the ACE2 protein functionalized MNPs with the set of antibodies and the set of competition probes that comprise the SARS-CoV-2 protein variant. Related systems and kits are also provided.
Resumen de: US2025368651A1
Disclosed herein are compound of Formula I, Formula II, or Formula III: or a pharmaceutically acceptable salt and/or solvate of any one or more thereof, pharmaceutical compositions including such compounds, and methods of treating disease by administering or contacting a subject with one or more of the above compounds.
Resumen de: US2025368689A1
Embodiments provided here include engineered viral proteins, such as but not limited to coronavirus spike proteins, e.g., SARS-CoV-2 spike proteins. These engineered viral proteins comprise modifications or mutations that facilitate secretion and efficient production. Exemplary engineered coronavirus spike proteins of the disclosure can combine mutations in regions of the spike proteins observed in various viruses of concern that have circulated in humans in one singular protein sequence. Additional embodiments provide nucleic acid molecules encoding the coronavirus spike proteins of the disclosure, pharmaceutical compositions and host cells comprising the proteins and/or nucleic acid molecules described here, methods and uses thereof for the prophylactic treatment of infection or disease associated with a coronavirus infection, and methods of producing such coronavirus spike proteins, as well as provide neutralizing antibody titers representing SARS-CoV-2 variants of concern, and high throughput, large scale bioreactor operation methods for production of human vaccines based on purified Spike proteins.
Resumen de: US2025369049A1
The present disclosure relates to methods for detecting and staging cellular immune responses to viral infections, including to SARS-CoV-2 and to methods for treating viral infections.
Resumen de: US2025367278A1
The disclosure provides coronavirus mRNA vaccines, including vaccines directed against spike proteins of one or more variant strains of SARS-CoV-2, as well as methods of using the vaccines.
Resumen de: US2025367270A1
Provided herein are, inter alia, peptides capable of binding viral proteins and thereby preventing viral infection, replication and spread (e.g., SARS CoV-2). The conjugates provided herein include a trimerizing domain (e.g., a collagen 18 trimerizing domain) attached through a peptide linker to a viral protein binding domain (e.g., a spike binding domain). The peptides and trimeric compositions provided herein exhibit a unique trimeric symmetry which results in superior binding affinities and low binding entropies providing for desirable compositions inhibit viral entry and treating viral infection.
Resumen de: US2025367225A1
The subject matter described herein relates to methods of zNKT cell activation by the 7DW8-5 glycolipid.
Resumen de: US2025368755A1
Disclosed are a peptide specifically binding to a PPC region of a SARS-CoV-2 spike protein and a composition for preventing SARS-CoV-2 infection using the same. The peptide includes a peptide sequence of DGRARQSQDDD or GSQIALRRRDE.
Resumen de: US2025345415A1
The present disclosure describes, inter alia, fusion polypeptides comprising a SARS-CoV-2 Spike polypeptide fragment comprising at least a portion of the N-terminal domain, domains CD1, RBM, and CD2, and at least a portion of CTD1, wherein the N- or C-terminus of the Spike polypeptide fragment is fused to a heterologous N- or C-terminal tag comprising at least two, at least three, or at least four amino acids, as well as polynucleotides and vectors expressing such fusion polypeptides, pharmaceutical compositions comprising the polypeptides or polynucleotides encoding them, host cells for their production, and methods of using such pharmaceutical compositions as vaccines or for generation of antibodies.
Resumen de: WO2024158875A1
Methods and compositions for treating SARS-CoV-2 and COVID-19 are disclosed. Sulfone-1H-pyrrole-2-carboxamides of the following formula inhibit the SARS-CoV-2 PLpro/NSP3 protein and are therefore useful for treating SARS-CoV-2 and COVID-19.
Resumen de: MX2025009957A
The present disclosure provides multi ci str onic vaccines and method for producing and using the same in preventing infection or transmission, or reducing severity of disease caused by influenza and/or SARS-Cov-2 virus in a subject. Multicistronic vaccines of the disclosure can be administered via intramuscular, intranasal, or inhalation route. In one particular embodiments, the disclosure provides a recombinant adenovirus comprising at least two different extraneous oligonucleotides that are capable of stimulating an immune response in a subject. Each of the oligonucleotide independently comprises an oligonucleotide that encodes either influenza or SARS-Cov-2 virus antigens.
Resumen de: US2025361277A1
In alternative embodiments, provided is a protease-responsive and surface-potential-tunable peptide-conjugated AIEgens (EGTP) for TMPRSS2 selective imaging and accurate inhibitor screening, where EGTP comprises four segments: the first is a polyglutamic acid (Glu, E for short in EGTP) that increases the solubility, blocks the positive charges and cell-penetrating ability of PyTPE; the second comprises a spacer trimylglycine (GGG, G) designed to enhance probe flexibility and reduce steric hindrance for TMPRSS2-substrate interactions; the third component second comprises a TMPRSS2-responsive peptide (QAR, T), which can be cleaved by TMPRSS2 after QAR sequence; and the fourth second comprises a positive charged AIEgens (PyTPE, P). In alternative embodiments, provided are main protease (Mpro)-responsive and modular-peptide-conjugated probes for the selective imaging and inhibition of SARS-CoV-2 infected cells via enzyme-instructed self-assembly and aggregation-induced emission.
Resumen de: WO2025242732A1
The present invention relates to the treatment of the COVID-19, here, the inventors generated potent non-neutralizing pan-SARS-CoV-2 mAb, notably the antibody C10, targeting a conserved region of the virus. Noteworthy, C10 demonstrated remarkable efficacy in recognizing nearly all known variants of the virus and effectively binding infected cells. Leveraging this pan-SARS-CoV-2 mAb, they have engineered CAR-T cells capable of efficiently killing lung epithelial cells infected with the virus. Overall, their work identifies a pan-SARS-Cov-2 able to target bona fide infected cells and provides a proof-of-concept for the potential use of CAR-T cell therapy in combating SARS-CoV-2 infections. Their findings also highlight the potential of non-neutralizing mAbs in mediating immune protection against emerging infectious diseases. Thus, the present invention relates to anti-spike antibodies, particularly in a purified form or in an isolated form and their use to treat SARS-CoV-2. Particularly, the present invention is defined by the claims.
Resumen de: US2025360134A1
The present invention relates to new specific 6-6 or 5-6 fused bicyclic compounds comprising pyrimidine or pyridine useful in the prevention and/or treatment of infectious diseases. In particular, the present invention relates to a compound of formula (I) wherein: Ar1 is a (C5-C11)arylene or (C5-C11)heteroarylene group, X is —CH—, —S—, —NR5 or —N—, Y is —CH—, —NR5—S— or —NR6—CH2—, T is —CH— and Q is —CH— or T is —N— and Q is —CR10— or —N—, provided that one or two of X, Q and Y comprise a heteroatom, and with the proviso that, at least one of R1, R2, and, if present, R5 or R6, contains a group —NH-Alk-NR3R4. The inventors showed that compounds of formula (I) present an activity against both W2 and 3D7 Plasmodium falciparum strains, an activity against T. brucei brucei but also an activity against SARS-CoV-2 virus, and that they are positive for G4 recognition. The invention also relates to the preparation process and to the therapeutic uses of the compounds of formula (I).
Resumen de: US2025360201A1
Pan-coronavirus vaccines for inducing efficient, powerful and long-lasting protection against all Coronaviruses infections and diseases, comprising multiple highly conserved large sequences which may comprise one or more conserved B, CD4 and CDS T cell epitopes that help provide multiple targets for the body to develop an immune response for preventing a Coronavirus infection and/or disease. In certain embodiments, the large sequences are conserved proteins or large sequences, e.g., sequences that are highly conserved among human coronaviruses and/or animal coronaviruses (e.g., coronaviruses isolated from animals susceptible to coronavirus infections).
Resumen de: US2025362296A1
The invention relates to methods and kits for determining a SARS-CoV-2 strain in a sample. The invention also provides methods and kits for detecting a single nucleotide polymorphism (SNP) in a target nucleic acid, wherein the target nucleic acid is a SARS-CoV-2 nucleic acid. The invention further provides methods and kits for detecting one or more antibody biomarkers in a sample.
Resumen de: US2025361316A1
Disclosed are a peptide, an antibody, or an antigen-binding fragment thereof, which specifically binds to an ACE2 (angiotensin-converting enzyme 2) receptor, and a composition for preventing SARS-CoV-2, the composition comprising the same. The peptide includes at least one peptide sequence selected from a group consisting of SEQ ID NO: 1 GHPVNSVLLDF, SEQ ID NO: 2 GHPRVNVGGDF, SEQ ID NO: 3 GVLGPRLLIDY and SEQ ID NO: 4 DGPINRTTIDY.
Resumen de: WO2024153586A1
The present invention relates to a new antisense oligonucleotide, a pharmaceutical composition comprising it and their use for preventing or treating infection by coronavirus, especially by SARS-CoV-2 virus which causes the infection disease COVID-19.
Resumen de: UA161330U
Method for polarization-interference reproduction of linear birefringence maps of supramolecular networks of dehydrated blood films of patients with a history of COVID-19 using multichannel laser polarization matrix mapping for algorithmic reproduction of integrally averaged linear birefringence maps of structural anisotropy of supramolecular networks of polycrystalline films of biological fluids and statistical evaluation of their structure. Samples of dehydrated blood films of patients with a history of COVID-19 are placed in the optical arrangement of a polarization Mach-Zahnder interferometer. A series of linearly polarized and circularly left- and right-polarized irradiating and reference laser beams are formed. For each polarization state, the irradiating beam is sequentially directed by a rotating mirror onto a sample of a dehydrated blood film, the laser images of which are projected by a polarization microlens into the plane of the photosensitive pixels of a digital camera. A series of reference beams are sequentially directed into the plane of the laser image of the dehydrated blood film using a rotating mirror, and interference patterns are formed that are transmitted by a linear polarizer in two rotations of the transmission plane to angles of 0° and 90°, which are sequentially recorded by the photosensitive pixels of a digital camera, with subsequent algorithmic digital holographic reproduction of layer-by-layer maps of linear birefringence of the structural an
Resumen de: ZA202502303B
A method and an apparatus utilizing targeted ion mobility spectrometry for the detection of the SARS-CoV-2 virus and its variants, by measuring the quantity of free polyamines including putrescine, spermidine, and spermine in a sublingual saliva sample. Other embodiments are capable of providing instant, cost effective, POC testing and test results for other viral and bacterial infections including influenza, acute and chronic respiratory conditions, certain forms of inflammation, and the detection of certain abnormal cells in human subjects.
Resumen de: EP4653459A1
The present invention relates to an antibody specifically binding to an IL-10 receptor and use thereof. The antibody targets IL-10 signaling and has an excellent effect of suppressing cytokine storm and excessive inflammation in severe inflammatory infectious diseases, and in particular, can be effectively used in suppressing inflammatory responses in severe SARS-CoV-2 infection and fatal SFTSV infection.
Resumen de: EP4653011A1
Provided in the present invention is a recombinant protein vaccine and/or an mRNA vaccine for preventing and/or treating infections of SARS-CoV-2 or a mutant thereof, and particularly provided is a method of using the mRNA vaccine and the recombinant protein vaccine. The vaccine can induce the generation of an antibody response and a cellular immune response in vivo to block the binding of the S protein of SARS-CoV-2 to the ACE2 receptor of host cells, so that the host resists coronavirus infections.
Nº publicación: EP4653454A1 26/11/2025
Solicitante:
WESTVAC BIOPHARMA CO LTD [CN]
WestVac Biopharma Co., Ltd
Resumen de: EP4653454A1
The present invention relates to the field of medicines, and relates to a protein and vaccine for resisting infection from a SARS-CoV-2 Omicron mutant strain and a subtype thereof. In order to solve the problem of lack of drugs for effective prevention and treatment for infections from the SARS-CoV-2 Omicron mutant strain and the subtype thereof, the present invention provides the protein and the vaccine for resisting infection from the SARS-CoV-2 Omicron mutant strain and the subtype thereof. The vaccine is optimally designed on the basis of an RBD sequence in an S protein of the SARS-CoV-2 Omicron mutant strain and substrains BA.4/5, BQ.1.1, and XBB.1.5, can help a host to resist a coronavirus infection, and particularly has a relatively good prevention and treatment effect on a cross infection caused by a SARS-CoV-2 Omicron mutant strain and subtype viruses thereof.
BOPI
Sede Electrónica
